Search results for "Survival Analysis"

showing 10 items of 748 documents

Palliative sedation in advanced cancer patients followed at home: A retrospective analysis

2012

Abstract CONTEXT: Data regarding palliative sedation at home in dying patients are lacking. OBJECTIVES: To describe the frequency, indication, and modality of palliative sedation (PS) in patients followed at home. METHODS: A retrospective analysis of home care cancer patients was performed. Patients who received PS before dying were selected and information about epidemiologic characteristics, indications, duration, drugs, and outcomes was collected. RESULTS: Of 370 medical charts of patients who died at home, 49 patients received PS before dying. PS was proposed by the team, relatives, or both in 63.3%, 4.1%, and 32.6% of cases, respectively. Delirium alone or in combination with other sym…

end of lifeMalePediatricsmedicine.medical_specialtyPalliative carePainComorbiditySettore MED/42 - Igiene Generale E ApplicataPalliative sedationadvanced cancer patientPalliative sedationRisk FactorsNeoplasmsRETROSPECTIVE STUDYPrevalenceMedicineHumansHypnotics and SedativesPALLIATIVE SEDATION; advanced cancer patients; RETROSPECTIVE STUDYIntensive care medicineSurvival rateGeneral NursingSurvival analysisNursing (all)2901 Nursing (miscellaneous)Retrospective StudiesTerminal Carepalliative carebusiness.industryDeliriumRetrospective cohort studymedicine.diseaseComorbidityHome Care ServicesSurvival AnalysisSurvival RateTreatment OutcomeAnesthesiology and Pain MedicineItalyend of life; home care; palliative care; Palliative sedation; Comorbidity; Delirium; Female; Home Care Services; Humans; Hypnotics and Sedatives; Italy; Male; Neoplasms; Pain; Palliative Care; Prevalence; Retrospective Studies; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)MidazolamDeliriumFemaleNeurology (clinical)medicine.symptombusinesshome caremedicine.drug
researchProduct

Machine learning for mortality analysis in patients with COVID-19

2020

This paper analyzes a sample of patients hospitalized with COVID-19 in the region of Madrid (Spain). Survival analysis, logistic regression, and machine learning techniques (both supervised and unsupervised) are applied to carry out the analysis where the endpoint variable is the reason for hospital discharge (home or deceased). The different methods applied show the importance of variables such as age, O2 saturation at Emergency Rooms (ER), and whether the patient comes from a nursing home. In addition, biclustering is used to globally analyze the patient-drug dataset, extracting segments of patients. We highlight the validity of the classifiers developed to predict the mortality, reaching…

feature importanceComputer scienceHealth Toxicology and MutagenesisPneumonia ViralDecision treelcsh:MedicineSample (statistics)Machine learningcomputer.software_genreLogistic regressionArticlesurvival analysisBiclustering03 medical and health sciencesBetacoronavirus0302 clinical medicineMachine learningRisk of mortalitygraphical modelsHumans030212 general & internal medicineGraphical modelPandemicsSurvival analysisInformática0303 health sciences030306 microbiologybusiness.industrySARS-CoV-2Decision Treeslcsh:RPublic Health Environmental and Occupational HealthCOVID-19Decision ruleSurvival analysisFeature importancemachine learningSpainArtificial intelligenceGraphical modelsbusinessCoronavirus Infectionscomputer
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Using Differential Geometry for Sparse High-Dimensional Risk Regression Models

2023

With the introduction of high-throughput technologies in clinical and epidemiological studies, the need for inferential tools that are able to deal with fat data-structures, i.e., relatively small number of observations compared to the number of features, is becoming more prominent. In this paper we propose an extension of the dgLARS method to high-dimensional risk regression models. The main idea of the proposed method is to use the differential geometric structure of the partial likelihood function in order to select the optimal subset of covariates.

high-dimensional datasparsitydgLARSrisk regression modelSettore SECS-S/01 - Statisticasurvival analysis
researchProduct

Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study.

2017

Background: More than 50% of patients with Crohn's disease require intestinal resection at least once. Postoperative recurrence (POR) is almost uniform if prophylactic treatment is not started early. Endoscopic monitoring is generally advised. We studied the incidence and management of recurrence in patients who had undergone intestinal resection. Methods: Practicrohn was an observational retrospective study performed in 26 Spanish hospitals including patients aged >= 18 years who underwent Crohn's disease-related ileocolonic resection between January 2007 and December 2010. We recorded preventive treatments, the incidence of clinical recurrence in daily practice, and associated risk factor…

intestinal resectionAdultMaleReoperationmedicine.medical_specialtymedicine.medical_treatment03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseInterquartile rangeRecurrenceRisk FactorsSecondary Preventionpostoperative recurrenceImmunology and AllergyMedicineHumansImmunologic FactorsPostoperative PeriodColectomyColectomyRetrospective StudiesCrohn's diseasemedicine.diagnostic_testbusiness.industryIncidence (epidemiology)IncidenceGastroenterologyRetrospective cohort studyEndoscopyBowel resectionmedicine.diseaseSurvival AnalysisEndoscopySurgeryCrohn's diseaseLogistic ModelsSpain030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologyFemaleprophylaxisbusinessFollow-Up StudiesInflammatory bowel diseases
researchProduct

Sex-specific selection on energy metabolism - selection coefficients for winter survival

2010

Selection for different fitness optima between sexes is supposed to operate on several traits. As fitness-related traits are often energetically costly, selection should also act directly on the energetics of individuals. However, efforts to examine the relationship between fitness and components of the energy budget are surprisingly scarce. We investigated the effects of basal metabolic rate (BMR, the minimum energy required for basic life functions) and body condition on long-term survival (8 winter months) with manipulated densities in enclosed populations of bank voles (Myodes glareolus). Here, we show that survival selection on BMR was clearly sex-specific but density-independent. Both…

media_common.quotation_subjectEnergeticsZoologyRegression analysisBiologyEnergy budgetbiology.organism_classificationCompetition (biology)ArvicolinaeBasal metabolic rateEcology Evolution Behavior and SystematicsSurvival analysisSelection (genetic algorithm)media_commonJournal of Evolutionary Biology
researchProduct

Impact of Prophylactic CD8-Depleted Donor-Lymphocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation and Alemtuzumab Mediated T-Ce…

2011

Abstract Abstract 4109 We have previously demonstrated that the application of CD8-depleted donor-lymphocyte infusions (DLI) is feasible after reduced-intensity conditioning and in vivo T-cell depletion by alemtuzumab. DLI overcome slow lymphocyte recovery associated with alemtuzumab-administration and improve anti-infectious immunity and reliably convert a decreasing T-cell chimerism (Meyer et al. Blood 2007 & BMT 2010). Here we provide clinical follow up data of 117 patients with different hematological diseases and a median observation time of 1 year (range, 1–86 months) post hematopoietic stem cell transplantation (HSCT). The majority of patients either suffered from an acute leukem…

medicine.medical_specialtyAcute leukemiabusiness.industrymedicine.medical_treatmentImmunologyContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationGraft-versus-host diseaseInternal medicinemedicineAlemtuzumabbusinessSurvival analysisMultiple myelomamedicine.drugBlood
researchProduct

2015

Summary Background The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial. Methods ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage I–IIa, grade 3 or clear cell histology) or more adv…

medicine.medical_specialtyBevacizumabbusiness.industrymedicine.diseaseChemotherapy regimenCarboplatinlaw.inventionSurgerychemistry.chemical_compoundOncologyRandomized controlled trialchemistryMaintenance therapylawInternal medicineClinical endpointMedicinebusinessOvarian cancerSurvival analysismedicine.drugThe Lancet Oncology
researchProduct

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with…

2009

Abstract Abstract 1909 Poster Board I-932 Background: The International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) utilizes five independent predictors of inferior survival; of these, a hemoglobin level <10 g/dL has the highest impact on survival (Cervantes et al. Blood 2009;113:2895). In the current study, we examined the additional prognostic impact of transfusion need at diagnosis or becoming transfusion-dependent in the first year of diagnosis. These events were also correlated with JAK2 or TET2 mutational status. Methods: Patients were selected from the Mayo Clinic PMF database based on availability of bone marrow histology and IPSS-relevant information at diag…

medicine.medical_specialtyBlood transfusionbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologymyelofibrosisTransfusion HistoryCell BiologyHematologyBiochemistrySettore MED/15 - Malattie Del SangueSurgeryTransplantationLog-rank testInternational Prognostic Scoring SystemInternal medicineCohortmedicinebusinessSurvival analysisBlood
researchProduct

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study

2010

Standard treatment of patients with breast cancer decreases with age and older persons are mostly excluded from clinical trials. We hypothesized that non-adherence to treatment guidelines occurs for women agedor =70 years and changes overall survival (OAS) and disease-free survival (DFS).We enrolled 1922 women agedor =50 years with histologically confirmed invasive breast cancer treated at the University of Ulm from 1992 to 2005. Adherence to guidelines and effects on OAS and DFS for women agedor =70 years was compared with that for younger women (50-69 years).Women70 years less often received recommended breast-conserving therapy (70-79 years: 74%-83%;79 years: 54%) than women agedor =69 y…

medicine.medical_specialtyBreast NeoplasmsMedical OncologyCohort StudiesBreast cancerGermanyInternal medicinemedicineHumansMastectomySurvival analysisAgedAged 80 and overGynecologyRadiotherapybusiness.industryStandard treatmentCarcinomaHazard ratioAge FactorsCancerProfessional PracticeHematologyMiddle Agedmedicine.diseaseSurvival AnalysisChemotherapy regimenOncologyChemotherapy AdjuvantFemaleGuideline AdherenceBreast diseasebusinessCohort studyAnnals of Oncology
researchProduct